Biosafety Evaluation of Equine Umbilical Cord-Derived Mesenchymal Stromal Cells (UC-MSCs) by Systematic Pathogen Screening in Peripheral Maternal Blood and Paired UC-MSCs

被引:7
|
作者
Denys, Marie [1 ]
Leon, Albertine [2 ,3 ]
Robert, Clement [4 ]
Saulnier, Nathalie [4 ]
Josson-Schramme, Anne [1 ]
Legrand, Loic [2 ,5 ]
Wimel, Laurence [6 ]
Maddens, Stephane [4 ]
Pronost, Stephane [2 ,5 ]
机构
[1] Univ Lyon, VetAgro Sup, 1 Ave Bourgelat, F-69280 Marcy Letoile, France
[2] LABEO Frank Duncombe, St Contest, France
[3] Normandie Univ, UNICAEN, U2RM, Caen, France
[4] Vetbiobank SAS, Marcy Letoile, France
[5] Normandie Univ, UNICAEN, BIOTARGEN, Caen, France
[6] French Horse & Riding Inst IFCE, Expt Farm, Chamberet, France
关键词
horse; mesenchymal stem cells; cellular therapy; vertical transmission; PCR; biosecurity; REAL-TIME PCR; THEILERIA-EQUI; BONE-MARROW; STEM-CELLS; QUANTITATIVE DETECTION; VERTICAL TRANSMISSION; MOLECULAR-DETECTION; BABESIA-CABALLI; VIRUS; EHV-1;
D O I
10.1089/bio.2019.0071
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: The growing interest in mesenchymal stromal cells (MSCs) in equine medicine, together with the development of MSC biobanking for allogeneic use, raises concerns about biosafety of such products. MSCs derived from umbilical cord (UC) carry an inherent risk of contamination by environmental conditions and vertical transmission of pathogens from broodmares. There is yet no report in the scientific literature about horses being contaminated by infected MSC products, and no consensus about systematic infectious screening of umbilical cord-derived mesenchymal stromal cells (UC-MSCs) to ensure microbiological safety of therapeutic products. Objectives: To develop a standard protocol to ensure UC-MSC microbiological safety and to assess the risk of vertical transmission of common intracellular pathogens from broodmares to paired UC-MSCs. Study Design and Methods: Eighty-four UC and paired peripheral maternal blood (PMB) samples were collected between 2014 and 2016. Sterility was monitored by microbiological control tests. Maternal contamination was tested by systematical PMB PCR screening for 14 pathogens and a Coggins test. In case of a PCR-positive result regarding one or several pathogen(s) in PMB, a PCR analysis for the detected pathogen(s) was then conducted on the associated UC-MSCs. Results: Ten out of 84 UC samples were contaminated upon extraction and 6/84 remained positive in primo culture. The remaining 78/84 paired PMB & UC-MSC samples were evaluated for vertical transmission; 37/78 PMB samples were PCR positive for Equid herpesvirus (EHV)-1, EHV-2, EHV-5, Theileria equi, Babesia caballi, and/or Mycoplasma spp. Hepacivirus was detected in 2/27 cases and Theiler Diseases Associated Virus in 0/27 cases (not performed on all samples due to late addition). All paired UC-MSC samples tested for the specific pathogen(s) detected in PMB were negative (37/37). Main Limitations: More data are needed regarding MSC susceptibility to most pathogens detected in PMB. Conclusions: In-process microbiological controls combined with PMB PCR screening provide a comprehensive assessment of UC-MSC exposure to infectious risk, vertical transmission risk appearing inherently low.
引用
收藏
页码:73 / 81
页数:9
相关论文
共 19 条
  • [1] IMMUNOMODULATORY CHARACTERIZATION OF AN UMBILICAL CORD-DERIVED MESENCHYMAL STROMAL CELLS (UC-MSCS)-BASED CELL THERAPY
    Mebarki, M.
    Abadie, C.
    Maheux, C.
    Churlaud, G.
    Boucher, H.
    Larghero, J.
    Faivre, L.
    Cras, A.
    CYTOTHERAPY, 2021, 23 (05) : S47 - S47
  • [2] UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS (UC-MSCS) THERAPY AS A ROSACEAE TREATMENT: A CASE REPORT
    Agustina, T.
    Halim, F.
    Sartika, C. R.
    Haifa, R.
    Karina, N.
    Naura, N. F. Farah
    Devi, D. K.
    Handayani, C. A.
    CYTOTHERAPY, 2022, 24 (05) : S84 - S84
  • [3] CASE REPORT: SAFETY PROFILE OF ALLOGENEIC UMBILICAL CORD MESENCHYMAL STEM CELLS (UC-MSCS) FOR ADRENOLEUKODYSTROPHY
    Adiputra, R. H.
    Prayitno, G. D.
    Aulia, M. A.
    Sartika, C. R.
    Haifa, R.
    Karina, N.
    Rahmawati, V.
    Devi, D. K.
    Shabrina, A.
    CYTOTHERAPY, 2021, 23 (05) : S70 - S71
  • [4] Reversibly immortalized human umbilical cord-derived mesenchymal stem cells (UC-MSCs) are responsive to BMP9-induced osteogenic and adipogenic differentiation
    Shu, Yi
    Yang, Chao
    Ji, Xiaojuan
    Zhang, Linghuan
    Bi, Yang
    Yang, Ke
    Gong, Mengjia
    Liu, Xing
    Guo, Qi
    Su, Yuxi
    Qu, Xiangyang
    Nan, Guoxin
    Zhao, Chen
    Zeng, Zongyue
    Yu, Xinyi
    Zhang, Ruyi
    Yan, Shujuan
    Lei, Jiayan
    Wu, Ke
    Wu, Ying
    An, Liping
    Huang, Shifeng
    Gong, Cheng
    Yuan, Chengfu
    Liu, Wei
    Huang, Bo
    Feng, Yixiao
    Zhang, Bo
    Dai, Zhengyu
    Shen, Yi
    Luo, Wenping
    Wang, Xi
    Haydon, Rex C.
    Luu, Hue H.
    Reid, Russell R.
    Wolf, Jennifer Moriatis
    Lee, Michael J.
    He, Tong-Chuan
    Li, Yasha
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2018, 119 (11) : 8872 - 8886
  • [5] THE COMBINATION TREATMENT OF UMBILICAL CORD MESENCHYMAL STEM CELLS (UC-MSCS) AND SECRETOME FOR DIABETIC FOOT ULCER: A CASE REPORT
    Prasetyo, A. T.
    Dwiyana, R. F.
    Sartika, C. R.
    Haifa, R.
    Karina, N.
    Naura, N. F. Farah
    Devi, D. K.
    Putri, A.
    CYTOTHERAPY, 2022, 24 (05) : S83 - S84
  • [6] UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS (UC-MSCS) ISOLATED WITH AN AUTOMATED PROTOCOL STIMULATE THE EXPANSION OF REGULATORY T CELLS (TREGS) VIA SOLUBLE OR DIFFUSIBLE MEDIATORS
    Jurczuk, V.
    Hernandez, S.
    Portocarrero, C.
    Martinez, G.
    Pyron, L.
    Umland, O.
    Xu, X.
    LoRusso, E. M.
    Rodriguez, R. U.
    Ricordi, C.
    Lanzoni, G.
    CYTOTHERAPY, 2022, 24 (05) : S57 - S57
  • [7] DEVELOPMENT OF A GMP BANKING PROCESS FOR UMBILICAL CORD MESENCHYMAL STROMAL CELLS (UC-MSCS) AND USE OF UC-MSC IN CHARACTERISATION ASSAYS, FUNCTIONAL ASSAYS AND GENE EDITING STUDIES
    McCahill, A.
    Hewit, K.
    Samuel, K.
    Colligan, D.
    Condie, A.
    Thomson, A.
    Mountford, J.
    CYTOTHERAPY, 2023, 25 (06) : S72 - S72
  • [8] COVID-19 disease treatment: pivotal challenges in the arena of umbilical cord-mesenchymal stem cells (UC-MSCs)
    Soliman, Al-Hassan
    Abdellatif, Mohamed
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2023, 11
  • [9] MANUFACTURING FRESHLY CULTURED UMBILICAL CORD-DERIVED MESENCHYMAL STROMAL CELLS (UC-MSCS) FOR A PHASE 1, MULTIPLE-DOSE CLINICAL TRIAL FOR COVID-19-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
    Khan, S.
    English, S.
    Hodgins, S.
    Sobh, M.
    Lalu, M.
    Watpool, I.
    Champagne, J.
    Fergusson, D.
    Jamieson, M.
    Thebaud, B.
    Stewart, D. J.
    Courtman, D. W.
    CYTOTHERAPY, 2021, 23 (05) : S55 - S55
  • [10] CASE SERIES: THE COMBINATION OF RECOMMENDED TREATMENT PROTOCOLS WITH ADD-ON SECRETOME FROM UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS (UC-MSCS) THERAPY AS A MEDICAL STRATEGY FOR COVID-19 TREATMENT
    Adhiarta, A.
    Sartika, C. R.
    Haifa, R.
    Karina, N.
    Naura, N.
    Devi, D. K.
    Pertiwi, V.
    CYTOTHERAPY, 2022, 24 (05) : S94 - S94